Helsinn is a global pharmaceutical company that builds, manufactures,
launches, and commercializes products to improve the quality of life for
patients with cancer and chronic disease, with a focus on supportive care,
oncology and dermato-oncology. Helsinn, headquartered in Lugano, Switzerland,
has direct commercial operations in the U.S. and an extensive network of
long-standing trusted partners enabling a commercial presence in more than 90
countries.